Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B
This real-world study suggests that switching to TAF is an effective and well-tolerated therapeutic strategy for NA-experienced CHB patients with PRT or LLV, offering a promising approach for treatment optimization.
Authors
- Tian‐Fu Liu (ORCID: https://orcid.org/0000-0001-9096-6981)
- Lingyi Zhang (ORCID: https://orcid.org/0000-0003-1690-578X)
- Aidi Ma
- Yin Kong
- Yaping Zhang
- Yuanyuan Liu (ORCID: https://orcid.org/0000-0001-6862-1928)
- Juan Li (ORCID: https://orcid.org/0000-0002-5775-9355)
- Xuan Hu (ORCID: https://orcid.org/0009-0000-3534-1604)
- Guangming Li (ORCID: https://orcid.org/0000-0003-2286-7679)
- Yongfang Li (ORCID: https://orcid.org/0000-0002-2565-2748)
Institutions
- Lanzhou University Second Hospital (CN)
- Anhui Provincial Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-14
- DOI
- https://doi.org/10.3389/fmed.2025.1592998
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Lanzhou University
- Natural Science Foundation of Gansu Province